This paper recognises that reproductive and fetal tissues are sources of stem cells and targets for regenerative medicine.
Such treatments in gynaecology are still in the preclinical and clinical phases, and the field of obstetrics has primarily focused on these interventions for fetal therapies. This paper discusses the possibilities, progress and problems of regenerative medicine to the genital tract and stem cell treatment of genetic diseases.
The paper also acknowledges the ethical issues and unknown risks and limitations that have arisen within this area.
This Scientific Impact Paper was developed prior to the emergence of the COVID-19 coronavirus.
This is the first edition of this Scientific Impact Paper.
Please note that the Scientific Advisory Committee regularly assesses the need to update. Further information on this review is available on request.
Developer declaration of interests
Available on request.